1.44

4.35% 0.06

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $1.44, with a volume of 668.87K. It is up +4.35% in the last 24 hours and down -6.49% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Previous Close:

$1.38

Open:

$1.4

24h Volume:

668.87K

Relative Volume:

0.77

Market Cap:

$145.10M

Revenue:

$27.08M

Net Income/Loss:

$-37.00M

P/E Ratio:

-2.7692

EPS:

-0.52

Net Cash Flow:

$-18.46M

1W Performance:

+7.46%

1M Performance:

-6.49%

6M Performance:

-31.10%

1Y Performance:

+9.92%

1-Day Range:

$1.37

$1.455

1-Week Range:

$1.27

$1.49

52-Week Range:

$0.9515

$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1152)

Industry

Diagnostics & Research (59)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2025-02-24

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	1.44	145.10M	27.08M	-37.00M	-18.46M	-0.52
TMO Thermo Fisher Scientific Inc	423.55	160.15B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	199.05	141.09B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	471.90	35.45B	3.90B	887.87M	798.08M	10.67
A Agilent Technologies Inc	108.63	30.37B	6.53B	1.26B	1.31B	4.35
IQV Iqvia Holdings Inc	153.48	26.50B	15.41B	1.37B	2.11B	7.50

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-25	Resumed	Cantor Fitzgerald	Overweight
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

03:11 AM

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World

03:11 AM

May 01, 2025

Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo

May 01, 2025

Apr 30, 2025

Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025

XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

Apr 30, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World

Apr 30, 2025

Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025

Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com

Apr 29, 2025

Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus

Apr 29, 2025

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com

Apr 29, 2025

Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com

Apr 29, 2025

Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan

Apr 29, 2025

Androgenetic Alopecia Treatment Market Generated - openPR.com

Apr 29, 2025

Apr 26, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Average Target Price from Brokerages - Defense World

Apr 26, 2025

Apr 25, 2025

Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance

Apr 25, 2025

Apr 24, 2025